Clinical trial | Treatments/arms | ND HGG (n) | Gliadel wafer plus RT/TMZ (n) | Median OS (months) | OS, 1Â year (%) | OS, 2Â years (%) | Median PFS (months) | PFS, 6 months (%) | PFS, 1Â year (%) |
---|---|---|---|---|---|---|---|---|---|
Aoki et al. [27] | Resection + Gliadel wafer + RT/TMZ | 16 | 16 | 20.2a | 100.0 % | 68.8 %, 44.4%a | NA | 75.0 % | 62.5 % |
Bock et al. [28] | Resection + Gliadel wafer + RT/TMZ | 44 | 44 | 12.7 | 58.0 % | 13.0 % | 7 | 63.0 % | 35.0 % |
Burri et al. [29] | Resection + Gliadel wafer + early TMZ (day 4) + RT/TMZ | 46 | 46 | 18 | 76.0 % | 33.0 % | 8.5 | 72.0 % | 33.0 % |
Duntze et al. [30] | Resection + Gliadel wafer + RT/TMZ | 92 | 65 | 18.8 | 70.0 % | 37.0 % | 10.5 | 74 % | 41.0 % |
McGirt et al. [31] | (1) Resection + Gliadel wafer + RT/TMZ | 33 | 33 | 21.3 | NA | 36.0 % | NA | 93.0 % | NA |
(2) Resection + Gliadel wafer + RT | 78 | 12.4b | NA | NA | NA | NA | NA | ||
(3) Resection/biopsy + RT/TMZ | 45 | 14.7c | NA | NA | NA | NA | NA | ||
Menei et al. [32] | (1) Resection + Gliadel wafer + RT/TMZ | 43 | 43 | 17 | NA | NA | NA | NA | NA |
(2) Resection + Gliadel wafer + other regimens | 40 | NA | NA | NA | NA | NA | NA | ||
Miglierini et al. [33] | Resection + Gliadel wafer + RT/TMZ | 24 | 22 | 19.2 | 78.0 % | 24.0 % | 12.3 | 81.50 % | 52.0 % |
Noel et al. [34] | (1) Resection + Gliadel wafer + RT/TMZ | 28 | 28 | 20.6 | 78.6 % | 40.9 % | 12.9 | NA | 52.0 % |
(2) Resection/biopsy + RT/TMZ | 37 | 20.8 | 78.4%d | 33.3 % | 14 | NA | 55.0%e | ||
Pan et al. [35] | Resection + Gliadel wafer + RT/TMZ | 21 | 21 | 17 | NA | 39.0 % | 8.5 | 71.0 % | NA |
Pavlov et al. [36] | Resection + Gliadel wafer + RT/TMZ | 83 | 61 | 19.5 | NA | NA | 8.5 | NA | NA |
Salvati et al. [37] | Resection + Gliadel wafer + RT/TMZ | 32 | 32 | NA | 100 % | NA | NA | 100 % | NA |